Immune checkpoints
Primary application for candidate characterization in immuno-oncology R&D.
Applications
Immune checkpoints first.
SYGPeD™ is primarily focused on immuno-oncology R&D, with PD‑1/PD‑L1 as the reference module and an architecture adaptable to additional biological targets.
Primary application
Screen and characterize candidates that modulate checkpoint–ligand interactions.
The SYGPeD™ workflow supports single-concentration comparison followed by dose-response confirmation when the design allows.
PD‑1 / PD‑L1
Reference module for comparative readout, screening and dose-response.
Candidate formats
Antibodies, VHHs, DARPins, peptides and additional formats depending on module configuration.
Modularity
An architecture tested beyond immune checkpoints.
Experimental validation on HER2, EPO and several cytokine models illustrates SYGPeD™ adaptability. Performance and readout type remain specific to each module.
HER2
Module implemented experimentally.
EPO
Module implemented experimentally.
Cytokine models
Several configurations used to evaluate architecture modularity.
R&D partners
Projects designed with biotech, pharma, CRO, hospitals and academic teams.
Biotech & Pharma
Comparative screening, candidate confirmation and co-development projects.
CRO & technology platforms
Pilot studies, module adaptation and targeted characterization workflows.
Hospitals & academia
Collaborative research and development of new RUO biosensing directions.
Your application is not listed?
We can evaluate module feasibility around your interaction, candidates and experimental decision.